Sequential EGFR inhibition sensitizes glioblastoma to temozolomide
Trends in Pharmacological Sciences · 2026-09 · 47 (9) · 952-954
DOI: 10.1016/j.tips.2026.07.010 ↗Kurz gefasst
Fachartikel in der Zeitschrift Trends in Pharmacological Sciences, 2026-09. Verfasst von Xiaozhou Yu und 2 weiteren Autor:innen. Beteiligte Einrichtung: The Ken & Ruth Davee Department of Neurology, The Lou and Jean Malnati Brain Tumor Institute, the Robert H. Lurie Comprehensive Cancer Center, Simpso…. Hauptthemen laut MEDLINE: ErbB Receptors, Glioblastoma, Dacarbazine, Brain Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 9 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NINDS NIH HHS, National Institutes of Health, National Institute of Neurological Disorders and Stroke.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Ken & Ruth Davee Department of Neurology, The Lou and Jean Malnati Brain Tumor Institute, the Robert H. Lurie Comprehensive Cancer Center, Simpson Querrey Institute for Epigenetics, Northwestern University Feinberg…
Förderung
- NINDS NIH HHS
- National Institutes of Health
- National Institute of Neurological Disorders and Stroke
Zitieren
APA
Yu, X., Wu, R., & Cheng, S. Y. (2026). Sequential EGFR inhibition sensitizes glioblastoma to temozolomide. Trends in Pharmacological Sciences, 47(9), 952-954. https://doi.org/10.1016/j.tips.2026.07.010
Vancouver
Yu X, Wu R, Cheng SY. Sequential EGFR inhibition sensitizes glioblastoma to temozolomide. Trends in Pharmacological Sciences. 2026;47(9):952-954. doi:10.1016/j.tips.2026.07.010
BibTeX
@article{Yu2026,
author = {Yu, Xiaozhou and Wu, Runxin and Cheng, Shi-Yuan},
title = {Sequential EGFR inhibition sensitizes glioblastoma to temozolomide},
journal = {Trends in Pharmacological Sciences},
year = {2026},
volume = {47},
number = {9},
pages = {952--954},
doi = {10.1016/j.tips.2026.07.010}
}
EUVIMED